Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano, Robert J. Gray, Della Makower et al. · New England Journal of Medicine · 2015
BACKGROUND: Prior studies with the use of a prospective-retrospective design including archival tumor samples have shown that gene-expression assays provide clinically useful prognostic information. However, a prospectively conducted study in a uniformly treated population provides the highest level of evidence supporting the clinical validity and usefulness of a biomarker. METHODS: We performed a prospective trial involving women with hormone-receptor-positive, human epidermal growth factor receptor type 2 (HER2)-negative, axillary node-negative breast cancer with tumors of 1.1 to 5.0 cm in the greatest dimension (or 0.6 to 1.0 cm in the greatest dimension and intermediate or high tumor grade) who met established guidelines for the consideration of adjuvant chemotherapy on the basis of clinicopathologic features. A reverse-transcriptase-polymerase-chain-reaction assay of 21 genes was performed on the paraffin-embedded tumor tissue, and the results were used to calculate a score indicating the risk of breast-cancer recurrence; patients were assigned to receive endocrine therapy without chemotherapy if they had a recurrence score of 0 to 10, indicating a very low risk of recurrence (on a scale of 0 to 100, with higher scores indicating a greater risk of recurrence). RESULTS: Of the 10,253 eligible women enrolled, 1626 women (15.9%) who had a recurrence score of 0 to 10 were assigned to receive endocrine therapy alone without chemotherapy. At 5 years, in this patient population, the rate of invasive disease-free survival was 93.8% (95% confidence interval [CI], 92.4 to 94.9), the rate of freedom from recurrence of breast cancer at a distant site was 99.3% (95% CI, 98.7 to 99.6), the rate of freedom from recurrence of breast cancer at a distant or local-regional site was 98.7% (95% CI, 97.9 to 99.2), and the rate of overall survival was 98.0% (95% CI, 97.1 to 98.6). CONCLUSIONS: Among patients with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who met established guidelines for the recommendation of adjuvant chemotherapy on the basis of clinicopathologic features, those with tumors that had a favorable gene-expression profile had very low rates of recurrence at 5 years with endocrine therapy alone. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00310180.).
Cited by 1,388 works. doi:10.1056/nejmoa1510764 Open-access PDF
Authors
- Joseph A. Sparano
- Robert J. Gray
- Della Makower
- Kathleen I. Pritchard
- Kathy S. Albain
- Daniel F. Hayes
- Charles E. Geyer
- Elizabeth Claire Dees
- Edith A. Perez
- John A. Olson
- Jo Anne Zujewski
- Tracy Lively
- Sunil Badve
- Thomas James Saphner
- Lynne I. Wagner
- Timothy Joseph Whelan
- Matthew J. Ellis
- Soonmyung Paik
- William C. Wood
- Peter M. Ravdin
References
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
- Cancer statistics, 2014
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
- Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- Global Patterns of Cancer Incidence and Mortality Rates and Trends
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer